Researchers at Stanford have developed chimeric antigen receptors (CARs) that target glypican-2 (GPC2) and can be used to treat solid tumors. CAR-engineered T cells have shown great promise as cancer therapeutics.
Stanford researchers have developed and validated a quality assurance (QA) phantom that will facilitate the translation of a frameless volumetric modulated arc therapy radiosurgery technique.
Stanford researchers developed a method to make large phase shifts with little or no power dissipation in integrated optics. The approach uses a directional coupler moved by a MEMS actuator to achieve a path delay, i.e. an effective change in refractive index.
Current injectable hydrogel materials have fast erosion and limited tunability of their mechanical properties at different stages of applications, limiting their biomedical applications.
Researchers at Stanford have discovered a powerful new optogenetic actuator- a novel red-shifted opsin. Optogenetics is a technique used to study function and communication between cells.
Heart failure has a prognosis worse than most cancers and affects over five million people in the United States alone. Although some medications for heart failure exist, many patients develop side effects or do not respond favorably to existing medications.
Researchers at Stanford have developed methods of using CRISPR/Cas9-mediated genome editing to treat patients with EGFR-mutant non-small-cell lung cancer (NSCLC). Approximately 85% of lung cancers are NSCLC.
Researchers at Stanford have developed a new therapeutic to promote survival of retinal ganglion cells (RGCs) and optic nerve regeneration after traumatic injury or optic neuropathies.
Dr. Manish Saggar at Stanford University has developed a new method to visualize and quantify transitions in brain activity, which may be used as a diagnostic tool for mental illness.